[ij] [ij] [ij] 
Email id

Asian Journal of Research in Pharmaceutical Science
Year : 2020, Volume : 10, Issue : 2
First page : ( 100) Last page : ( 102)
Print ISSN : 2231-5640. Online ISSN : 2231-5659.
Article DOI : 10.5958/2231-5659.2020.00019.3

Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate

Kshirsager Sandip S.1,*, Dr. Shaikh Siraj N.1, Patil Narendra B.2, Patil Ketan B.2

1Department of Pharmaceutics, Ali Allana College of Pharmacy, Akkalkuwa, Maharashtra

2Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha, Dist-Dhule, Maharashtra

*Corresponding Author E-mail: sandipkshirsagar53@gmail.com

Online published on 3 June, 2020.


Cancer is leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018. Breast cancer 2.09 million death in 2018. Approximately 70% of deaths from cancer occurs in low-and middle-income countries. Human epidermal growth factor receptor (HER) 2 is overexpressed in 20–25% of breast cancer and has historically been poor prognostics marker. Niratinib maleate is an anti breast cancer drug.it is crystalline form and chemically (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl) methoxy] phenyl] amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino) but-2-enamide maleate. It an oral, irreversible pan-Erb B receptor tyrosine kinase inhibitor and it can effectively inhibit the activity of Erb B1, ErbB2 tyrosine kinase.



Breast cancer, tyrosine kinase, Niratinib maleate, HER (Human epidermal growth factor receptor).


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
775,867,526 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.